
About Nexgenia
Nexgenia is a Healthcare company based in Seattle (United States) founded in 2011. It develops and manufactures proprietary polymers and polymer-containing magnetic nanoparticles for diagnostics and life science applications. It operates in the Healthcare, Technology, and Chemicals & Materials sectors. Nexgenia has raised $3.98 million across 5 funding rounds from investors including The W Fund and Gamespools. The company has 2 employees. Nexgenia offers products and services including Smart Magnetic Nanoparticles. Its focus areas include High Tech, Advanced Materials, Nanostructures and Metal and Metalloid. Its legal entity is NEXGENIA INC. Its competitors include Avidity Biosciences, Sutro Biopharma and Vividion Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Nexgenia develops and manufactures reagent systems that combine stimuli-responsive polymers with magnetic nanoparticles to enable rapid recognition of target molecules. The company develops and validates stimuli-responsive nanoparticles with the ability to co-aggregate for cell separation for use in cancer immunotherapies and other medical applications. It offers specialty chemicals and materials for manufacturers of in vitro diagnostic assays, and for life science applications related to assays and molecular separations; and distributors of products for diagnostic testing.
- Headquarters Seattle, United States
- Employees 2
- SectorsHealthcareTechnology Chemicals & Materials
- Website nexgeniacorp.com
- Social X
- Legal Name Nexgenia Inc
- Total Equity Funding$3.98M (USD)
in 5 rounds
- Latest Funding Round$119.1K (USD), Debt – Conventional
May 2018
- InvestorsThe W Fund
& 1 more
- Employee Count2
Products & Services of Nexgenia
Nexgenia offers a comprehensive portfolio of products and services, including Smart Magnetic Nanoparticles.
Improve speed and sensitivity for molecular and cell separations in testing
Funding Insights of Nexgenia
Nexgenia has successfully raised a total of $3.98M across 5 strategic funding rounds. The most recent funding activity was a Debt β Conventional round of $119.1 thousand completed in May 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $3.98M
- Total Rounds 5
- Last Round Debt – Conventional β $119,099
- First Round $249,900
(Aug 2014)
- Investors Count 2
All 5 funding rounds of Nexgenia with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2018 | $119,099 | Debt – Conventional | β | β | β |
| Aug 2016 | $1.86M | Series A | β | β | β |
| Jun 2015 | $1.62M | Series A | β | β | β |
| Oct 2014 | $500,000 | Seed | β | β | |
| Aug 2014 | $249,900 | Grant | β | β |
2 investors in total: 2 institutional.
Investors in Nexgenia
Nexgenia has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include The W Fund and Gamespools.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| thewfund.com | ||||
Gamespools is recognized as an online slot gaming platform. | lsdfa.org | Indonesia |
Investor details for Nexgenia
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Nexgenia
1 people are tracked at Nexgenia (1 in leadership); the tracked headcount is 2.
| Name | Role | Group |
|---|---|---|
Ron Myers | CEO | Leadership |
Complete people profiles for Nexgenia
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Nexgenia
3 dated milestones of Nexgenia across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Nexgenia is founded.
- Funding First funding round of $250K.
- Funding Latest funding round, Debt β Conventional, of $119K.
Competitors of Nexgenia
Nexgenia has 3 listed competitors in our database, 3 of them funded. They include Avidity Biosciences, Sutro Biopharma and Vividion Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| vividion.com | 2016 | Oceanside, United States | $270.5M | 123 | Developing novel drugs based on a proteome-wide ligand and target discovery platform |
Detailed competitors of Nexgenia
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Nexgenia (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Nexgenia
Nexgenia was founded in 2011 and raised its 1st funding round 3 years after it was founded.
Nexgenia is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Nexgenia is a funded company, having raised a total of $3.98M across 5 funding rounds to date. The company's 1st funding round was a Grant of $249.9K, raised on Aug 2014.
Nexgenia has 2 employees.
Nexgenia develops and manufactures reagent systems that combine stimuli-responsive polymers with magnetic nanoparticles to enable rapid recognition of target molecules. The company develops and validates stimuli-responsive nanoparticles with the ability to co-aggregate for cell separation for use in cancer immunotherapies and other medical applications. It offers specialty chemicals and materials for manufacturers of in vitro diagnostic assays, and for life science applications related to assays and molecular separations; and distributors of products for diagnostic testing.
Nexgenia's top competitors include Sutro Biopharma, Avidity Biosciences and Vividion Therapeutics.
Nexgenia offers Smart Magnetic Nanoparticles.
Nexgenia has 2 investors. Key investors include The W Fund, and Gamespools.
Nexgenia operates through Nexgenia Inc.